Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
- 1st Edition, Volume 12 - November 17, 2020
- Imprint: Academic Press
- Editors: Andrew Freywald, Franco Vizeacoumar
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 1 3 1 0 - 0
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 1 3 1 1 - 7
Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticit… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteBiological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance.
Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges.
- Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field
- Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients
- Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies
Cancer researchers, medical scientists, clinicians, graduate students
- Cover image
- Title page
- Table of Contents
- Copyright
- Cover Image Insert
- Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy”
- About the Series Editor
- Aims and Scope of Volume
- About the Volume Editors
- Preface
- Contributors
- Chapter 1: Luminal A breast cancer resistance mechanisms and emerging treatments
- Abstract
- Introduction
- Targeting the PI3K/Akt/mTOR pathway
- Targeting the cell cycle
- Targeting DNA repair pathways
- Immune checkpoint inhibitors
- New sequential treatments and more combination treatments used earlier
- Monitoring tumor evolution via circulating tumor DNA
- Conclusion
- Chapter 2: Development of novel androgen receptor inhibitors to overcome castrate-resistant prostate cancer
- Abstract
- Introduction
- Current treatment of CRPC
- Resistance to current AR therapeutics
- Novel small molecule inhibitors to overcome resistance
- Conclusions
- Chapter 3: Autotaxin is an important component of the tumor microenvironment and a major modulator of therapy responses for breast cancer
- Abstract
- Introduction
- Tumor microenvironment
- Cellular components
- Noncellular components
- The autotaxin-lysophosphatidate-inflammatory cycle as part of the wound healing process
- The autotaxin-lysophosphatidate-inflammatory cycle and its role in breast cancer progression
- Roles of the LPPs in regulating the ATX-LPA-inflammatory cycle
- The autotaxin-lysophosphatidate-inflammatory cycle and its effects on chemotherapy
- The autotaxin-lysophosphatidate-inflammatory cycle and its effects on outcomes from radiotherapy (RT)
- LPA signaling and the “radiation fibrosis syndrome”
- Experimental approaches to studying TME
- Conclusion
- Chapter 4: Revisiting immunogenic cell death to improve treatment response in cancer
- Abstract
- Introduction
- Cell death and immunogenicity don’t always go hand in hand
- Exploiting the clinical potential of ICD in anticancer therapies
- ICD effects of anticancer microbial therapies
- Improving vulnerability to immune checkpoint blockade through ICD
- Factors affecting magnitude of ICD seen in response to therapy
- Capitalizing on immunogenicity to promote long-term antitumor immune responses
- Conclusion
- Chapter 5: Overcoming therapeutic resistance in glioblastoma: Moving beyond the sole targeting of the glioma cells
- Abstract
- Glioblastoma: A major clinical challenge
- Mouse models of glioblastoma
- Models for clinically relevant disease reservoirs in GBM
- Repurposing disulfiram in the therapeutic setting of glioblastoma
- Brain extracellular matrix and its impact on glioma progression
- Extracellular vesicles and their role in glioma progression (secreted guidance molecules)
- Brain tumor cellular microenvironment and its ability to be harnessed for therapeutic gain
- Additional concepts for harnessing the TME for therapeutic gain
- Chapter 6: Preventing phenotypic plasticity in cancer to mitigate therapy resistance
- Abstract
- Tumor heterogeneity as a driver of therapy resistance and metastasis
- Stochastic acquisition of plasticity: Mutations enable plasticity
- Stress-induced acquisition of plasticity
- Evolution of therapies targeting phenotypic plasticity
- Chapter 7: Targeting leukemia stem cells in T-cell acute lymphoblastic leukemia (T-ALL)
- Abstract
- Introduction: The concept of leukemia stem cells and its clinical impact
- Leukemia stem cells in T-cell acute lymphoblastic leukemia (T-ALL)
- Targetable signaling pathways of leukemia stem cell activity in T-ALL
- Conclusion and therapeutic perspectives
- Chapter 8: Tumor metabolic reprogramming in therapeutic resistance
- Abstract
- Introduction
- Targeting glucose metabolism in cancer
- Targeting mitochondrial metabolism in cancer
- Targeting amino acid metabolism in cancer
- Metabolic reprogramming and therapeutic resistance
- Cellular metabolism, redox balance, and therapeutic resistance
- Metabolic reprogramming and immunotherapy
- Conclusions
- Chapter 9: From genetic data and structures to drug development: New approaches to target Eph receptors
- Abstract
- Introduction
- Eph and ephrin function in angiogenesis and cancer
- Structural features of Eph receptors and their ligands
- New paradigm: Head-to-tail interactions of unbound Eph ectodomains
- Catalytically inactive Ephs
- Strategies to target Eph receptors for therapeutic purposes
- Using genomics to discover new Eph receptor-based targets for therapy
- New avenues to target Eph receptors
- Conclusions
- Chapter 10: Anastasis, recovery from the brink of death as a mechanism of drug resistance
- Abstract
- Introduction
- Anastasis: Cell survival following activation of caspase 3
- Therapeutic consequences of anastasis
- Molecular mechanisms and therapeutic targeting of anastasis
- Potential mechanism of initiation of anastasis
- Conclusion
- Chapter 11: Overcoming drug resistance in osteosarcoma and pancreatic adenocarcinoma with radioimmunotherapy
- Abstract
- Introduction
- RIT of osteosarcoma
- RIT of pancreatic ductal carcinoma
- Conclusions
- Index
- Edition: 1
- Volume: 12
- Published: November 17, 2020
- No. of pages (Hardback): 308
- No. of pages (eBook): 308
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780128213100
- eBook ISBN: 9780128213117
AF
Andrew Freywald
Dr. Andrew Freywald, obtained his PhD in molecular and cell biology at the Weizmann Institute of Science, Israel, and completed his post-doctorate training in molecular immunology and cancer research at the Hospital for Sick Children, Toronto, Canada. His current research interests include cancer cell biology and tumor biology. He also serves as a scientific advisor for the biotech industry. The work of his research team at the College of Medicine, University of Saskatchewan focuses on investigating and targeting molecular mechanisms that determine tumor aggressiveness, and treatment resistance. His research program has been supported by several granting agencies, including CIHR, CCSRI, SHRF CRS, CFI, SCA, PCC, CBCF and TFRI, and also by the Be Like Bruce organization and the College of Medicine, University of Saskatchewan.
Affiliations and expertise
College of Medicine, University of Saskatchewan, CanadaFV
Franco Vizeacoumar
Dr. Franco J. Vizeacoumar, obtained his PhD in cell biology at the University of Alberta, Canada, and did his post-doctorate at the University of Toronto, Canada. His lab is working on developing genotype-directed cancer therapies for solid tumors by applying basic biological concepts called synthetic lethality and synthetic dosage lethality. The long term goal of his research group is to build a unified human genetic network that will capture genetic dependencies of cancer cells and define key therapeutic targets. The work in the Vizeacoumar lab has been supported by multiple granting agencies, such as CIHR, SCA, CRS, SHRF, CFI, TFRI, PCC, and also by the Be Like Bruce organization and the College of Medicine at the University of Saskatchewan.
Affiliations and expertise
Saskatchewan Cancer Agency, College of Medicine, University of Saskatchewan, CanadaRead Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance on ScienceDirect